EW Edwards Lifesciences Corporation Common Stock
NYSE · Health Care · SEC EDGAR で表示 ↗ 終値 10月 2, 2026 10-K/10-Q 8月 4, 2026
$85.15
· 52週範囲の%
· 安値より上
· 高値へ
$72.3052週安値
$96.2952週高値
時価総額 (MRQ)
$49.10B
P/E (TTM)
48.9
EPS (TTM)
$1.74
収益 (TTM)
$6.51B
あなたのバッジ
52週レンジ
$72–$96
アナリスト評価
BUY
目標株価
$101
P/E
48.9
ROE
9.5%
純利益率
15.4%
バッジストリップは空です。このページ上の任意の指標をピン留めしてください。
EW 株価スナップショット 価格、時価総額、P/E、EPS、ROE、負債/資本、52週レンジ
株価
$85.15
時価総額 (MRQ)
$49.10B
P/E (TTM)
48.9
EPS (TTM)
$1.74
収益 (TTM)
$6.51B
ROE (TTM)
9.5%
負債/自己資本 (MRQ)
0.1
52週レンジ
$72–$96
EW 株価チャート 技術指標付きの日次 OHLCV — パン、ズーム、ビューのカスタマイズ
範囲
バー
バーの粒度は選択した期間に合わせて調整されます。バーの始値/高値/安値/終値を確認するにはチャートにカーソルを合わせてください。
株式分割
| 権利落ち日 | 分割 | タイプ |
|---|---|---|
| 2020年6月1日 | 3-for-1 | 順 |
| 2015年12月14日 | 2-for-1 | 順 |
| 2010年5月28日 | 2-for-1 | 順 |
Edwards Lifesciences Corporation Common Stock について Wikipediaからの企業概要
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027.
History
Edwards Lifesciences was originally founded by electrical engineer Miles "Lowell" Edwards in 1958, a graduate of Oregon State University. Edwards invented the first medically proven and adopted artificial heart valve. Dr. Albert Starr, a surgeon at the Oregon Health and Sciences University, is credited as the first to successfully implant the Starr-Edwards mitral valve in a patient in 1960. As a result of the successful heart implant, Edwards established manufacturing in Santa Ana, California the same year to continue his research in pulmonary devices.
Edwards' valves are still in operation today. An early patient lived a record 48 years with the implant before requiring a replacement.
Edwards was acquired by Baxter in 1985. It was spun off from Baxter in 2000.
In 2017, Edwards completed the acquisition of Valtech Cardio for $340 million. Also in 2017, Edwards acquired Harpoon Medical of Baltimore, Maryland for $100 million. Harpoon, founded in 2013, developed a minimally invasive heart surgery product for mitral valve repair to treat degenerative mitral regurgitation. At the time of the acquisition, the product was not available on any market.
On April 18, 2019, Edwards completed the acquisition of CAS Medical Systems of Branford, Connecticut for ~$100 million.
Edwards Sapien 3 and Sapien 3 Ultra Transcatheter Heart Valve systems were FDA-approved for the treatment of patients at low risk for death or major complications associated with open-heart surgery on August 16, 2019. These products are used to treat patients with severe aortic stenosis without utilizing open-heart surgery.
In 2020, Edwards co-sponsored the Virtual ISPOR-FDA Summit centered on patient preference information in medical device regulatory decisions.
In December 2021, the FDA approved the SAPIEN 3 transcatheter valve in combination with the Alterra adaptive prestent for the treatment of severe pulmonary regurgitation.
In February 2024, the FDA approved Edwards' EVOQUE tricuspid valve replacement system, the first transcatheter therapy approved in the United States for the treatment of tricuspid regurgitation. In May 2024, Edwards launched the SAPIEN 3 Ultra RESILIA valve in Europe.
In June 2024, the company received FDA approval for a new implant designed to manage heart failure issues, called the Cordella pulmonary artery sensor.
In July 2024, Edwards made agreements with Affluent Medical for an equity stake, IP licensing and an exclusive option to acquire its Kephalios subsidiary. The same month, Edwards announced it would acquire Innovalve Bio Medical for approximately $300 million, and JenaValve Technology and Endotronix for $1.2 billion.
In August 2024, Edwards acquired JC Medical from Genesis MedTech, gaining its J-Valve transcatheter aortic valve replacement system for the treatment of aortic regurgitation.
In 2023, Edwards announced that its critical care business unit would be spun off into a separate entity. In June 2024 Edwards instead agreed to sell the unit to BD for $4.2 billion. The sale closed on September 3, 2024.
In May 2025, the FDA approved the SAPIEN 3 platform, including the SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA valves, for the treatment of severe aortic stenosis in asymptomatic patients, marking the first FDA approval of TAVR therapy for this patient population.
In September 2025, Edwards completed the full acquisition of heart failure monitoring company Vectorious Medical Technologies.
In January 2026, the FDA approved the SAPIEN M3 mitral valve replacement system, the first transcatheter mitral valve replacement therapy using a transseptal approach to receive FDA approval for the treatment of mitral regurgitation.
Business segments
Prior to September 2024, its products were categorized into four areas: surgical valve technologies, transcatheter heart valves, transcatheter mitral and tricuspid therapies, and critical care. In September 2024, Edwards completed the sale of its Critical Care product group to BD. Since September 2024, its products are categorized into four areas: surgical valve technologies, transcatheter heart valves, transcatheter mitral and tricuspid therapies, and implantable heart failure management (IHFM).
Transcatheter Heart Valve
The company's SAPIEN family of transcatheter aortic heart valves is made of bovine pericardial tissue mounted within a balloon-expandable, cobalt-chromium frame and is deployed via catheter. Edwards introduced the transcatheter heart valve replacement procedure to U.S. patients unable to undergo open-heart surgery with FDA approval of the SAPIEN transcatheter valve in 2011. The indication was expanded in November 2012 to include patients at a high risk for death or serious complications associated with open-heart surgery. In 2021, the FDA cleared Edwards’ SAPIEN 3 transcatheter valve with the Alterra adaptive prestent for pulmonic heart valve replacement. In May 2024, Edwards launched the SAPIEN 3 Ultra RESILIA valve in Europe.
Transcatheter Mitral and Tricuspid Therapies
The Transcatheter Mitral and Tricuspid Therapies business segment develops transcatheter heart valve repair and replacement technologies to treat mitral and tricuspid valve diseases. In September 2022, the FDA approved Edwards' PASCAL Precision transcatheter valve repair system for the treatment of degenerative mitral regurgitation.
Surgical
The Surgical business segment involves the use of Edwards' RESILIA tissue technology, developed to help limit valve calcification. Edwards estimates that more than 450,000 patients around the world have either undergone SAVR or TAVR with an Edwards RESILIA valve.
Critical Care
Before its sale, the Critical Care business segment included pulmonary artery catheters, disposable pressure transducers and advanced hemodynamic monitoring systems. The portfolio also included a line of balloon catheter-based vascular products, surgical clips and inserts. In 2023, it was announced that the critical care business unit was to be spun off into its own entity, however in 2024 the critical care department was purchased by BD for $4.2 billion.
Organizational culture
Edwards Lifesciences Foundation
The Edwards Lifesciences Foundation launched in 2014 and supports programs designed to treat underserved people to reduce heart valve disease.
Since the initiative launched in 2014, Edwards and its foundation have contributed more than $100 million in financial and technology donations through "Every Heartbeat Matters" (EHM), reaching over 4 million underserved structural heart patients globally.
出典: Wikipedia (英語), CC BY-SA 4.0 · Wikipediaで表示 ↗
セクターHealth Care
業種Health Care
従業員16,000
国US
10年間のパフォーマンス 収益、純利益、利益率、EPSのトレンド
収益$6.07B2016-12-31 → 2025-12-31
EPS$1.832016-12-31 → 2025-12-31
フリーキャッシュフロー$1.33B2016-12-31 → 2025-12-31
純利益率15.4%2023-12-31 → 2025-12-31
バリュエーションと指標
バリュエーション P/E、P/S、P/B、EV/EBITDA比率 — 株は割高か割安か？
| 指標 | 5年トレンド | EW | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| P/E (TTM) | 48.95年平均 ≈35.1 | ≈35.1 | 31.0 | 割高 | |
| P/S (TTM) | 7.55年平均 ≈10.2 | ≈10.2 | 5.0 | 割高 | |
| 株価純資産倍率 (MRQ) | 4.65年平均 ≈7.5 | ≈7.5 | 5.0 | 適正価格 | |
| EV/EBITDA (TTM) | 28.15年平均 ≈30.5 | ≈30.5 | 27.0 | 割高 | |
| 株価FCF倍率 (TTM) | 34.25年平均 ≈72.6 | ≈72.6 | · | · | |
| 株価収益率（P/CF） (TTM) | 28.55年平均 ≈49.3 | ≈49.3 | 26.4 | 割高 | |
| EV/売上高 (TTM) | 7.05年平均 ≈9.8 | ≈9.8 | · | · | |
| EV/FCF (TTM) | 31.75年平均 ≈69.1 | ≈69.1 | · | · | |
| 株価純資産倍率（P/TB） (MRQ) | 5.35年平均 ≈10.1 | ≈10.1 | · | · | |
| PEG Ratio (PEGレシオ) | ≈6.9 | · | · | · |
同業他社の中央値は、指標ごとに標準化された基準で計算されており、この銘柄に表示されているTTM/MRQ基準と常に一致するとは限りません。
収益性 粗利益率、営業利益率、純利益率、ROE、ROA、ROIC
| 指標 | 5年トレンド | EW | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| 粗利益率 (TTM) | 77.8%5年平均 ≈78.1% | ≈78.1% | 65.9% | トップクラス | |
| 営業利益率 (TTM) | 22.3%5年平均 ≈27.3% | ≈27.3% | 24.8% | トップクラス | |
| EBITDAマージン (TTM) | 24.8%5年平均 ≈29.9% | ≈29.9% | 29.5% | 同水準 | |
| 税引前利益率 (TTM) | 21.8%5年平均 ≈28.3% | ≈28.3% | 24.0% | トップクラス | |
| 純利益率 (TTM) | 15.4%5年平均 ≈39.3% | ≈39.3% | 17.8% | 弱い | |
| ROA (TTM) | 7.3%5年平均 ≈20.4% | ≈20.4% | 7.9% | 同水準 | |
| ROE (TTM) | 9.5%5年平均 ≈27.7% | ≈27.7% | 15.9% | 弱い | |
| ROIC | 9.6%5年平均 ≈17.3% | ≈17.3% | 11.5% | 弱い |
財務健全性 負債、流動性、支払能力 — バランスシートの健全性
| 指標 | 5年トレンド | EW | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| 負債資本倍率 (MRQ) | 0.15年平均 ≈0.1 | ≈0.1 | 0.6 | 低負債 | |
| 流動比率 (MRQ) | 4.55年平均 ≈3.5 | ≈3.5 | 1.6 | 高流動性 | |
| クイックレシオ (MRQ) | 3.35年平均 ≈2.3 | ≈2.3 | 0.9 | 高流動性 | |
| 長期負債/株主資本 (MRQ) | 0.15年平均 ≈0.1 | ≈0.1 | 0.6 | 低負債 |
成長 収益、EPS、純利益の成長率：前年比、3年CAGR、5年CAGR
| 指標 | 5年トレンド | EW | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| Revenue YoY (収益（前年比）) | 11.6%5年平均 ≈7.4% | ≈7.4% | · | · | |
| Revenue CAGR 3Y (収益（3年CAGR）) | 10.8%5年平均 ≈5.5% | ≈5.5% | · | · | |
| Revenue CAGR 5Y (収益（5年CAGR）) | 6.7% | · | · | · | |
| EPS YoY | -73.7%5年平均 ≈41.8% | ≈41.8% | · | · | |
| Net Income YoY (純利益（前年比）) | -74.3%5年平均 ≈29.2% | ≈29.2% | · | · | |
| EPS CAGR 3Y (EPS年平均成長率 3年) | -9.1%5年平均 ≈18.3% | ≈18.3% | · | · | |
| EPS CAGR 5Y (EPS年平均成長率 5年) | 7.1% | · | · | · | |
| Net Income CAGR 3Y (純利益年平均成長率 3年) | -11.0% | · | · | · |
資本効率 総資産回転率、棚卸資産回転率、売掛金回転率
| 指標 | 5年トレンド | EW | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| Asset Turnover (総資産回転率) | 0.55年平均 ≈0.6 | ≈0.6 | 0.5 | 弱い | |
| Inventory Turnover (棚卸資産回転率) | 1.25年平均 ≈1.3 | ≈1.3 | 2.4 | 弱い | |
| Receivables Turnover (売掛金回転率) | 9.65年平均 ≈8.8 | ≈8.8 | 6.8 | トップクラス | |
| Revenue / Employee (年間売上高 ÷ 従業員数（yfinanceの報告ヘッドカウント）。派生値 — SEC-XBRLの保存概念ではありません。) | ≈$379.2K | · | · | · |
バリュエーション · ≈ 5年平均 · 業界中央値 · 中央値に対する評価
決算履歴 EPS実績 vs 予想、サプライズ%、達成率、次回決算日
平均サプライズ
2.6%
次回決算
10月 28, 2026
| 期間 | レポート | EPS Actual | EPS 予想 | サプライズ |
|---|---|---|---|---|
| 2026年6月30日 | 7月 22, 2026 | $0.78 | $0.76 | 2.3% |
| 2026年3月31日 | $0.78 | $0.75 | 4.2% | |
| 2025年12月31日 | $0.58 | $0.64 | -8.8% | |
| 2025年9月30日 | $0.67 | $0.61 | 9.6% | |
| 2025年6月30日 | $0.67 | $0.64 | 4.4% | |
| 2025年3月31日 | $0.64 | $0.61 | 4.1% |
完全なファンダメンタルズ 年次別全指標 — 損益計算書、貸借対照表、キャッシュフロー
損益計算書
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B | $4.39B | $4.35B | $3.72B | $3.44B | $2.96B | $2.49B | $2.32B | |
| Cost of Revenue | $1.33B | $1.12B | $978M | $724M | $1.25B | $1.08B | $1.11B | $939M | $875M | $797M | $617M | $626M | |
| Gross Profit | $4.73B | $4.32B | $4.03B | $3.74B | $3.98B | $3.31B | $3.23B | $2.78B | $2.56B | $2.17B | $1.88B | $1.70B | |
| R&D Expense | $1.08B | $1.05B | $963M | $844M | $903M | $761M | $753M | $622M | $553M | $442M | $383M | $346M | |
| SG&A Expense | $2.09B | $1.79B | $1.58B | $1.36B | $1.49B | $1.23B | $1.24B | $1.09B | $991M | $905M | $851M | $858M | |
| Operating Income | $1.26B | $1.38B | $1.31B | $1.50B | $1.69B | $898M | $1.15B | $748M | $1.09B | $751M | · | · | |
| Interest Expense | · | · | $18M | $19M | $18M | $16M | $21M | $30M | $23M | $19M | $17M | $17M | |
| Interest Income | $169M | $120M | $67M | $36M | $17M | $23M | $32M | $32M | $20M | $11M | $8M | $6M | |
| Other Non-op | $7M | $69M | $14M | $5M | $13M | $12M | $8M | $4M | $-1M | $-5M | $-4M | $-8M | |
| Pretax Income | $1.27B | $1.55B | $1.37B | $1.52B | $1.70B | $917M | $1.17B | $761M | $1.03B | $738M | $622M | $1.14B | |
| Income Tax | $217M | $152M | $152M | $196M | $199M | $93M | $120M | $39M | $451M | $168M | $128M | $333M | |
| Net Income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B | · | · | · | · | · | · | · | |
| EPS (Basic) | $1.84 | $6.98 | $2.31 | $2.46 | $2.41 | $1.32 | $1.68 | $1.15 | $2.77 | $2.67 | $2.30 | $3.81 | |
| EPS (Diluted) | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 | $1.30 | $1.64 | $1.13 | $2.70 | $2.61 | $2.25 | $3.74 | |
| Shares (Basic) | 584,800,000 | 597,700,000 | 606,700,000 | 619,000,000 | 623,300,000 | 622,600,000 | 624,800,000 | 627,600,000 | 210,900,000 | 213,000,000 | 215,500,000 | 213,000,000 | |
| Shares (Diluted) | 585,800,000 | 599,300,000 | 609,400,000 | 624,200,000 | 631,200,000 | 631,900,000 | 636,700,000 | 640,900,000 | 215,900,000 | 217,800,000 | 220,300,000 | 217,000,000 | |
| EBITDA | $1.42B | $1.53B | $1.68B | $1.89B | $1.83B | $1.00B | $1.24B | $826M | $82M | $71M | $66M | $69M |
貸借対照表
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.94B | $3.05B | $1.13B | $769M | $863M | $1.18B | $1.18B | $714M | $818M | $930M | $718M | $654M | |
| Short-term Investments | $1.29B | $931M | $500M | $446M | $604M | $219M | $338M | $242M | $519M | $341M | $506M | $785M | |
| Receivables | $660M | $609M | $772M | $643M | $582M | $515M | $544M | $457M | $439M | $366M | $315M | $288M | |
| Inventory | $1.13B | $1.09B | $904M | $876M | $727M | $802M | $641M | $607M | $555M | $397M | $340M | $297M | |
| Prepaid Expense | $135M | $121M | $129M | $110M | $85M | $75M | $59M | $54M | $61M | $46M | $45M | $49M | |
| Other Current Assets | $339M | $348M | $225M | $196M | $237M | $208M | $168M | $132M | $117M | $112M | $66M | $122M | |
| Current Assets | $6.74B | $6.29B | $4.04B | $3.10B | $3.18B | $3.09B | $2.98B | $2.29B | $2.55B | $2.24B | $2.05B | $2.23B | |
| PP&E (Net) | $1.81B | $1.69B | $1.59B | $1.63B | $1.55B | $1.40B | $1.06B | $868M | $680M | $580M | $482M | $443M | |
| PP&E (Gross) | $2.66B | $2.48B | $2.29B | $2.38B | $2.20B | $1.99B | $1.57B | $1.32B | $1.09B | $961M | $854M | $808M | |
| Accum. Depreciation | $850M | $794M | $699M | $750M | $655M | $598M | $512M | $455M | $412M | $381M | $372M | $365M | |
| Goodwill | $1.77B | $1.78B | $1.15B | $1.06B | $1.17B | $1.17B | $1.17B | $1.11B | $1.13B | $626M | $628M | $376M | |
| Intangibles | $1.13B | $1.18B | $399M | $285M | $324M | $331M | $336M | $343M | $468M | $205M | $205M | $23M | |
| Other Non-current Assets | $730M | $722M | $463M | $299M | $111M | $120M | $102M | $34M | $109M | $123M | $132M | $49M | |
| Total Assets | $13.70B | $13.06B | $9.36B | $8.29B | $8.50B | $7.24B | $6.49B | $5.32B | $5.67B | $4.51B | $4.06B | $3.52B | |
| Accounts Payable | $228M | $197M | $187M | $202M | $204M | $196M | $180M | $134M | $117M | $97M | $64M | $58M | |
| Current Liabilities | $1.81B | $1.51B | $1.20B | $1.02B | $1.03B | $894M | $902M | $877M | $1.42B | $532M | $476M | $426M | |
| Capital Leases | $83M | $79M | $65M | $70M | $69M | $73M | $59M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $37M | · | · | · | · | · | |
| Other Non-current Liabilities | $362M | $373M | $251M | $218M | $267M | $252M | $203M | $150M | $147M | $115M | $285M | $113M | |
| Total Liabilities | $3.36B | $2.99B | $2.64B | $2.49B | $2.67B | $2.66B | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | · | · | · | $594M | $1.04B | $822M | · | · | |
| Total Debt | $598M | $598M | $597M | $596M | $596M | $595M | $594M | $594M | $1.04B | $822M | $600M | $598M | |
| Common Stock | $659M | $655M | $650M | $646M | $642M | $636M | $218M | $215M | $212M | $243M | $239M | $129M | |
| Retained Earnings | $14.24B | $13.17B | $8.99B | $7.59B | $6.07B | $4.57B | $3.74B | $2.69B | $1.96B | $3.91B | $3.34B | $2.84B | |
| Treasury Stock | $7.09B | $6.19B | $5.02B | $4.14B | $2.42B | $1.90B | $1.28B | $1.02B | $252M | $2.50B | $1.84B | $1.56B | |
| AOCI | $-238M | $-244M | $-243M | $-255M | $-158M | $-161M | $-156M | $-138M | $-133M | $-198M | $-183M | $-101M | |
| Stockholders' Equity | $10.34B | $10.00B | $6.65B | $5.81B | $5.84B | $4.57B | $4.15B | $3.14B | $2.96B | $2.62B | $2.50B | $2.19B | |
| Liabilities + Equity | $13.70B | $13.06B | $9.36B | $8.29B | $8.50B | $7.24B | $6.49B | $5.32B | $5.67B | $4.51B | $4.06B | $3.52B | |
| Shares Outstanding | 580,700,000 | 654,800,000 | 650,500,000 | 646,300,000 | 642,000,000 | 636,400,000 | 218,100,000 | 207,700,000 | 209,700,000 | 211,600,000 | 215,400,000 | 107,800,000 |
キャッシュフロー
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $157M | $155M | $145M | $140M | $135M | $107M | $89M | $77M | $82M | $71M | $66M | $69M | |
| Stock-based Comp | $158M | $162M | $139M | $127M | $109M | $93M | $81M | $71M | $62M | $57M | $50M | $48M | |
| Deferred Tax | $-66M | $-163M | $-242M | $-262M | $-44M | $-52M | $10M | $-21M | $27M | $-24M | $-16M | $-67M | |
| Amort. of Intangibles | $8M | $6M | $2M | $2M | $8M | $5M | $5M | $2M | $8M | $8M | $7M | $8M | |
| Restructuring | $13M | $33M | · | · | · | · | · | · | · | · | $0 | $0 | |
| Other Non-cash | $273M | $-3.79B | $-529M | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $1.60B | $542M | $896M | $1.22B | $1.73B | $1.05B | $1.18B | $927M | $1.00B | $704M | $550M | $1.02B | |
| CapEx | $260M | $252M | $253M | $245M | $326M | $407M | $254M | $239M | $168M | $176M | $103M | $83M | |
| Investing Cash Flow | $-713M | $2.31B | $174M | $252M | $-1.72B | $-531M | $-596M | $77M | $-647M | $-212M | $-316M | · | |
| Debt Issued | · | · | $0 | $0 | $5M | $16M | $19M | $688M | $995M | $254M | $31M | $226M | |
| Net Debt Issued | · | · | $0 | $0 | $5M | $16M | $19M | $688M | $995M | $254M | $31M | $226M | |
| Stock Repurchased | $893M | $1.16B | $880M | $1.73B | $513M | $625M | $263M | $796M | $763M | $662M | $280M | $301M | |
| Net Stock Activity | $-893M | $-1.16B | $-880M | $-1.73B | $-513M | $-625M | $-263M | $-796M | $-763M | $-662M | $-280M | $-301M | |
| Financing Cash Flow | $-957M | $-983M | $-711M | $-1.58B | $-356M | $-487M | $-116M | $-1.10B | $-473M | $-268M | $-159M | · | |
| Net Change in Cash | $-119M | $1.91B | $375M | $-95M | $-333M | $16M | $468M | $-104M | $-112M | $212M | $65M | $233M | |
| Taxes Paid | $490M | $1.20B | $470M | · | · | · | · | · | · | · | · | $275M | |
| Free Cash Flow | $1.33B | $290M | $643M | $974M | $1.41B | $647M | $925M | $688M | $833M | $528M | $447M | $939M | |
| Levered FCF | · | · | $627M | $957M | $1.39B | $633M | $906M | $660M | $820M | $513M | $433M | $927M |
収益性
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.0% | 79.5% | 77.0% | 79.9% | 76.1% | 75.4% | 74.4% | 74.8% | 74.5% | 73.1% | 75.2% | 73.1% | |
| Operating Margin | 20.8% | 25.4% | 25.6% | 32.5% | 32.3% | 20.5% | 26.4% | 20.1% | · | · | · | · | |
| Net Margin | 17.7% | 76.8% | 23.4% | · | · | · | · | · | · | · | · | · | |
| Pretax Margin | 21.0% | 28.5% | 26.6% | 32.8% | 32.5% | 20.9% | 26.8% | 20.4% | 30.1% | 24.9% | 25.0% | 49.2% | |
| EBITDA Margin | 23.4% | 28.2% | 28.0% | 35.1% | 34.9% | 22.9% | 28.4% | 22.2% | 2.4% | 2.4% | 2.6% | 2.9% | |
| ROA | 8.0% | 37.2% | 15.9% | · | · | · | · | · | · | · | · | · | |
| ROE | 10.6% | 50.1% | 22.5% | · | · | · | · | · | · | · | · | · | |
| ROIC | 9.6% | 11.7% | 18.5% | 23.5% | 23.2% | 15.6% | 21.7% | 19.0% | · | · | · | · |
流動性と支払能力
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | 4.2 | 3.4 | 3.0 | 3.1 | 3.5 | 3.3 | 2.6 | 1.8 | 4.2 | 4.3 | 5.3 | |
| Quick Ratio | 2.7 | 3.0 | 2.0 | 1.8 | 2.0 | 2.1 | 2.3 | 1.6 | 1.3 | 3.1 | 3.2 | 4.0 | |
| Debt / Equity | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.4 | 0.3 | 0.2 | 0.3 | |
| LT Debt / Equity | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.3 | 0.2 | 0.3 | |
| Interest Coverage | · | · | 87.2 | 91.1 | 91.9 | 56.8 | 55.4 | 25.0 | · | · | · | · |
効率性
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.7 | 0.6 | 0.7 | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | |
| Inventory Turnover | 1.2 | 1.1 | 1.4 | 1.3 | 1.6 | 1.5 | 1.8 | 1.6 | 1.8 | 2.2 | 1.9 | 2.1 | |
| Receivables Turnover | 9.6 | 7.9 | 8.5 | 8.8 | 9.5 | 8.3 | 8.7 | 8.3 | 8.7 | 8.7 | 8.3 | 7.9 |
1株あたり
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $17.80 | $16.99 | $11.06 | $9.55 | $9.35 | $7.33 | $19.84 | $15.12 | $14.10 | $12.38 | $11.62 | $20.33 | |
| Revenue / Share | $10.36 | $9.08 | $9.85 | $8.62 | $8.29 | $6.94 | $20.49 | $17.43 | $15.91 | $13.61 | $11.32 | $21.41 | |
| Cash Flow / Share | $2.72 | $0.90 | $1.47 | $1.95 | $2.74 | $1.67 | $5.56 | $4.34 | $4.63 | $3.23 | $2.50 | $9.42 | |
| Cash / Share | $5.06 | $5.17 | $1.90 | $1.26 | $1.38 | $1.90 | $5.64 | $3.44 | $3.90 | $4.40 | $3.34 | $6.06 | |
| EPS (TTM) | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 | $1.30 | $1.64 | $1.13 | $2.70 | $2.61 | $2.25 | $3.74 |
成長率
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.6% | 8.6% | 12.2% | -14.7% | 19.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 10.8% | 1.3% | 4.5% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.7% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -73.7% | 203.0% | -5.7% | 2.5% | 83.1% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -9.1% | 43.1% | 20.9% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 7.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -74.3% | 197.7% | -7.8% | 1.2% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -11.0% | 40.6% | · | · | · | · | · | · | · | · | · | · |
バリュエーション（TTM）
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B | $4.39B | $4.35B | $3.72B | $3.44B | $2.96B | $2.49B | $2.32B | |
| Net Income TTM | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B | $235M | $235M | $235M | $235M | $235M | $235M | $235M | |
| Market Cap | $49.50B | $43.57B | $45.83B | $45.39B | $80.85B | $56.95B | $16.26B | $10.60B | $7.88B | $6.61B | $5.67B | $2.29B | |
| Enterprise Value | $45.88B | $40.20B | $44.79B | $44.77B | $79.98B | $56.15B | $15.34B | $10.24B | $7.58B | $6.16B | $5.05B | $1.45B | |
| P/E | 46.6 | 10.6 | 33.2 | 30.6 | 54.4 | 70.2 | 47.4 | 45.2 | 13.9 | 12.0 | 11.7 | 5.7 | |
| P/S | 8.2 | 8.0 | 9.1 | 10.2 | 15.5 | 13.0 | 3.7 | 2.8 | 2.3 | 2.2 | 2.3 | 1.0 | |
| P/B | 4.8 | 4.4 | 6.9 | 7.8 | 13.9 | 12.5 | 3.9 | 3.4 | 2.7 | 2.5 | 2.3 | 1.0 | |
| P / Tangible Book | 6.7 | 6.2 | 9.0 | 10.2 | 18.6 | 18.6 | · | · | · | · | · | · | |
| P / Cash Flow | 31.0 | 80.4 | 51.2 | 37.3 | 46.7 | 54.0 | 13.8 | 11.4 | 7.9 | 9.4 | 10.3 | 2.2 | |
| P / FCF | 37.1 | 150.3 | 71.3 | 46.6 | 57.5 | 88.0 | 17.6 | 15.4 | 9.5 | 12.5 | 12.7 | 2.4 | |
| EV / EBITDA | 32.3 | 26.2 | 26.7 | 23.7 | 43.8 | 55.9 | 12.4 | 12.4 | 92.5 | 86.5 | 76.7 | 21.1 | |
| EV / FCF | 34.4 | 138.7 | 69.7 | 46.0 | 56.9 | 86.7 | 16.6 | 14.9 | 9.1 | 11.7 | 11.3 | 1.5 | |
| EV / Revenue | 7.6 | 7.4 | 8.9 | 10.0 | 15.3 | 12.8 | 3.5 | 2.8 | 2.2 | 2.1 | 2.0 | 0.6 | |
| Earnings Yield | 2.1% | 9.4% | 3.0% | 3.3% | 1.8% | 1.4% | 2.1% | 2.2% | 7.2% | 8.4% | 8.6% | 17.6% |
損益計算書
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.74B | $1.65B | $1.57B | $1.55B | $1.53B | $1.41B | $1.39B | $1.35B | $1.37B | $1.33B | $1.01B | $1.24B | $1.28B | $1.22B | $430M | $1.32B | |
| Cost of Revenue | $392M | $363M | $343M | $345M | $344M | $302M | $292M | $263M | $276M | $287M | $141M | $251M | $257M | $330M | $-99M | $254M | |
| Gross Profit | $1.35B | $1.29B | $1.23B | $1.21B | $1.19B | $1.11B | $1.09B | $1.09B | $1.09B | $1.04B | $870M | $993M | $1.03B | $992M | $529M | $1.07B | |
| R&D Expense | $279M | $263M | $268M | $281M | $276M | $255M | $271M | $253M | $272M | $257M | $215M | $243M | $244M | $261M | $131M | $234M | |
| SG&A Expense | $561M | $522M | $603M | $515M | $502M | $466M | $492M | $421M | $448M | $428M | $354M | $382M | $410M | $436M | $201M | $377M | |
| Operating Income | $513M | $478M | $151M | $307M | $411M | $395M | $313M | $351M | $366M | $349M | $291M | $366M | $264M | $388M | $198M | $402M | |
| Interest Income | $30M | $34M | · | · | $37M | $36M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-op | $17M | $72M | $3M | $3M | $-1M | $3M | $33M | $28M | $2M | $6M | $3M | $7M | $2M | $2M | $6M | $-2M | |
| Pretax Income | $520M | $459M | $90M | $348M | $400M | $434M | $390M | $403M | $384M | $371M | $311M | $388M | $275M | $399M | $211M | $407M | |
| Income Tax | $278M | $78M | $26M | $56M | $64M | $70M | $45M | $41M | $20M | $46M | $21M | $53M | $21M | $58M | $11M | $64M | |
| Net Income | $242M | $381M | $91M | $291M | $333M | $358M | $386M | $3.07B | $366M | $352M | $370M | $385M | $307M | $340M | $398M | $344M | |
| EPS (Basic) | $0.42 | $0.66 | $0.16 | $0.50 | $0.57 | $0.61 | $0.65 | $5.14 | $0.61 | $0.58 | $0.61 | $0.63 | $0.51 | $0.56 | $0.66 | $0.55 | |
| EPS (Diluted) | $0.42 | $0.66 | $0.16 | $0.50 | $0.56 | $0.61 | $0.65 | $5.13 | $0.61 | $0.58 | $0.61 | $0.63 | $0.50 | $0.56 | $0.65 | $0.55 | |
| Shares (Basic) | 576,400,000 | 579,200,000 | · | 584,700,000 | 587,000,000 | 586,900,000 | · | 597,200,000 | 602,100,000 | 601,600,000 | · | 607,000,000 | 606,900,000 | 607,500,000 | · | 619,800,000 | |
| Shares (Diluted) | 577,600,000 | 580,700,000 | · | 585,700,000 | 587,900,000 | 587,800,000 | · | 598,100,000 | 604,300,000 | 604,100,000 | · | 609,500,000 | 610,300,000 | 610,900,000 | · | 624,500,000 | |
| EBITDA | $513M | $518M | · | $307M | $411M | $431M | · | $351M | $369M | $426M | · | $418M | $327M | $424M | · | $402M |
貸借対照表
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.91B | $2.45B | $2.94B | $2.69B | $3.27B | $3.14B | $3.05B | $3.68B | $1.64B | $1.22B | · | $1.41B | $1.04B | $872M | · | $1.25B | |
| Short-term Investments | $1.35B | $1.23B | $1.29B | $1.16B | $789M | $758M | $931M | $770M | $345M | $473M | · | $454M | $467M | $382M | · | $491M | |
| Receivables | $770M | $776M | $660M | $693M | $697M | $669M | $609M | $716M | $778M | $818M | · | $740M | $754M | $718M | · | $618M | |
| Inventory | $1.13B | $1.12B | $1.13B | $1.14B | $1.14B | $1.11B | $1.09B | $1.10B | $1.02B | $1.21B | · | $1.03B | $980M | $914M | · | $758M | |
| Prepaid Expense | $119M | $136M | $135M | $125M | $110M | $111M | $121M | $115M | $110M | $138M | · | $133M | $123M | $119M | · | $88M | |
| Other Current Assets | $360M | $330M | $339M | $323M | $314M | $304M | $348M | $231M | $252M | $251M | · | $236M | $217M | $190M | · | $268M | |
| Current Assets | $6.82B | $6.23B | $6.74B | $6.36B | $6.58B | $6.21B | $6.29B | $6.73B | $4.52B | $4.17B | · | $4.07B | $3.65B | $3.26B | · | $3.51B | |
| PP&E (Net) | $1.84B | $1.82B | $1.81B | $1.74B | $1.73B | $1.70B | $1.69B | $1.68B | $1.64B | $1.77B | · | $1.68B | $1.66B | $1.65B | · | $1.57B | |
| PP&E (Gross) | · | · | $2.66B | · | · | · | $2.48B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $850M | · | · | · | $794M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $1.95B | $1.82B | $1.77B | $1.77B | $1.78B | $1.78B | $1.78B | $1.61B | $1.15B | $1.25B | $1.15B | $1.30B | $1.30B | $1.31B | $1.06B | $1.16B | |
| Intangibles | $1.38B | $1.23B | $1.13B | $1.13B | $1.17B | $1.17B | $1.18B | $956M | $417M | $447M | · | $430M | $431M | $447M | · | $266M | |
| Other Non-current Assets | $616M | $739M | $730M | $785M | $743M | $743M | $722M | $684M | $790M | $768M | · | $447M | $412M | $294M | · | $316M | |
| Total Assets | $13.87B | $13.32B | $13.70B | $13.27B | $13.49B | $13.02B | $13.06B | $12.97B | $10.10B | $9.74B | · | $9.37B | $9.00B | $8.65B | · | $8.64B | |
| Accounts Payable | $210M | $181M | $228M | $165M | $162M | $172M | $197M | $173M | $186M | $212M | · | $191M | $193M | $181M | · | $155M | |
| Current Liabilities | $1.51B | $1.41B | $1.81B | $1.59B | $1.40B | $1.39B | $1.51B | $1.94B | $1.22B | $1.11B | · | $1.24B | $1.16B | $1.08B | · | $918M | |
| Capital Leases | $82M | $80M | $83M | $75M | $79M | $78M | $79M | $85M | $74M | $77M | · | $70M | $64M | $66M | · | $67M | |
| Other Non-current Liabilities | $382M | $351M | $362M | $363M | $379M | $358M | $373M | $323M | $257M | $266M | · | $240M | $243M | $260M | · | $221M | |
| Total Liabilities | $3.14B | $2.99B | $3.36B | $3.07B | $2.88B | $2.83B | $2.99B | $3.36B | $2.59B | $2.55B | · | $2.64B | $2.56B | $2.59B | · | $2.42B | |
| Total Debt | $599M | $598M | · | $598M | $598M | $598M | · | $598M | $597M | $597M | · | $597M | $597M | $596M | · | $596M | |
| Common Stock | $662M | $660M | $659M | $658M | $658M | $656M | $655M | $654M | $654M | $652M | · | $650M | $649M | $647M | · | $646M | |
| Retained Earnings | $14.86B | $14.62B | $14.24B | $14.15B | $13.86B | $13.53B | $13.17B | $12.78B | $9.71B | $9.34B | · | $8.62B | $8.24B | $7.93B | · | $7.19B | |
| Treasury Stock | $7.67B | $7.51B | $7.09B | $7.05B | $6.46B | $6.45B | $6.19B | $6.09B | $5.18B | $5.02B | · | $4.58B | $4.40B | $4.39B | · | $3.28B | |
| AOCI | $-215M | $-221M | $-238M | $-250M | $-264M | $-254M | $-244M | $-252M | $-220M | $-233M | · | $-250M | $-256M | $-255M | · | $-256M | |
| Stockholders' Equity | $10.62B | $10.33B | $10.34B | $10.21B | $10.55B | $10.13B | $10.00B | $9.55B | $7.44B | $7.12B | · | $6.66B | $6.38B | $5.98B | · | $6.22B | |
| Liabilities + Equity | $13.87B | $13.32B | $13.70B | $13.27B | $13.49B | $13.02B | $13.06B | $12.97B | $10.10B | $9.74B | · | $9.37B | $9.00B | $8.65B | · | $8.64B | |
| Shares Outstanding | 576,600,000 | 577,000,000 | 580,700,000 | 580,700,000 | 587,900,000 | 586,200,000 | 588,600,000 | 589,800,000 | 602,300,000 | 602,400,000 | 650,500,000 | 606,500,000 | 607,900,000 | 606,000,000 | 646,300,000 | 619,400,000 |
キャッシュフロー
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $43M | $41M | $43M | $39M | $38M | $37M | $43M | $34M | $40M | $38M | $37M | $37M | $36M | $35M | $35M | $35M | |
| Stock-based Comp | $42M | $45M | $39M | $41M | $38M | $40M | $32M | $42M | $44M | $45M | $30M | $33M | $37M | $39M | $28M | $30M | |
| Restructuring | · | · | $5M | $100.0K | · | · | $0 | $33M | · | · | · | $0 | · | · | · | · | |
| Other Non-cash | · | $-423M | · | · | · | $-154M | · | · | · | $-488M | · | · | · | · | · | · | |
| Operating Cash Flow | $652M | $44M | $451M | $574M | $290M | $280M | $-128M | $352M | $372M | $-54M | $137M | $412M | $34M | $314M | $283M | $310M | |
| CapEx | $67M | $65M | $97M | $58M | $49M | $56M | $50M | $52M | $85M | $65M | $88M | $55M | $48M | $62M | $69M | $60M | |
| Investing Cash Flow | $-193M | $-93M | $-198M | $-428M | $-172M | $85M | $-577M | $2.70B | $125M | $63M | $14M | $89M | $70M | $500.0K | $95M | $-202M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Stock Repurchased | $153M | $422M | $41M | $589M | $6M | $259M | $100M | $901M | $158M | $200.0K | $448M | $174M | $8M | $249M | $866M | $100M | |
| Net Stock Activity | · | $-422M | · | · | · | $-259M | · | · | · | $-200.0K | · | · | · | $-249M | · | · | |
| Financing Cash Flow | $-300.0K | $-451M | $-11M | $-740M | $53M | $-258M | $29M | $-977M | $-97M | $62M | $-413M | $-143M | $52M | $-207M | $-838M | $-70M | |
| Net Change in Cash | $462M | $-492M | $245M | $-595M | $141M | $90M | $-625M | $2.03B | $429M | $81M | $-266M | $366M | $171M | $104M | $-479M | $49M | |
| Free Cash Flow | · | $-21M | · | · | · | $224M | · | · | · | $-119M | · | · | · | $253M | · | · |
収益性
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.5% | 78.0% | · | 77.8% | 77.5% | 78.6% | · | 80.6% | 79.4% | 75.9% | · | 76.3% | 77.6% | 77.4% | · | 80.8% | |
| Operating Margin | 29.5% | 29.0% | · | 19.8% | 26.8% | 28.0% | · | 25.9% | 26.6% | 24.2% | · | 28.2% | 21.4% | 26.6% | · | 30.5% | |
| Net Margin | 13.9% | 23.1% | · | 18.7% | 21.8% | 25.3% | · | 226.7% | 26.4% | 22.0% | · | 26.0% | 20.1% | · | · | · | |
| Pretax Margin | 29.9% | 27.8% | · | 22.4% | 26.1% | 30.7% | · | 29.7% | 27.9% | 25.6% | · | 29.7% | 22.1% | 27.3% | · | 30.9% | |
| EBITDA Margin | 29.5% | 31.4% | · | 19.8% | 26.8% | 30.5% | · | 25.9% | 26.6% | 26.7% | · | 28.2% | 21.4% | 29.0% | · | 30.5% | |
| ROA | 1.8% | 2.9% | · | 2.2% | 2.8% | 3.1% | · | 27.5% | 3.8% | 3.8% | · | 4.3% | 3.5% | · | · | · | |
| ROE | 2.3% | 3.7% | · | 2.9% | 3.7% | 4.2% | · | 37.9% | 5.3% | 5.4% | · | 6.0% | 5.0% | · | · | · | |
| ROIC | 2.1% | 3.6% | · | 2.4% | 3.1% | 3.1% | · | 3.1% | 4.3% | 4.3% | · | 5.0% | 4.2% | 5.1% | · | 5.0% |
流動性と支払能力
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | 4.4 | · | 4.0 | 4.7 | 4.5 | · | 3.5 | 3.7 | 3.8 | · | 3.3 | 3.2 | 3.0 | · | 3.8 | |
| Quick Ratio | 3.3 | 3.2 | · | 2.9 | 3.4 | 3.3 | · | 2.7 | 2.3 | 2.3 | · | 2.1 | 2.0 | 1.8 | · | 2.6 | |
| Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| LT Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 |
効率性
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.2 | 0.3 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.3 | |
| Receivables Turnover | 2.4 | 2.3 | · | 2.2 | 2.1 | 1.9 | · | 1.9 | 1.8 | 2.1 | · | 2.2 | 2.2 | 2.2 | · | 2.2 |
1株あたり
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $18.41 | $17.90 | · | $17.57 | $17.94 | $17.28 | · | $16.18 | $12.35 | $11.82 | · | $10.98 | $10.49 | $9.86 | · | $10.04 | |
| Revenue / Share | $3.01 | $2.84 | · | $2.65 | $2.61 | $2.40 | · | $2.26 | $2.29 | $2.65 | · | $2.43 | $2.51 | $2.39 | · | $2.11 | |
| Cash Flow / Share | · | $0.08 | · | · | · | $0.48 | · | · | · | $-0.09 | · | · | · | $0.51 | · | · | |
| Cash / Share | $5.04 | $4.24 | · | $4.62 | $5.57 | $5.36 | · | $6.23 | $2.73 | $2.03 | · | $2.33 | $1.72 | $1.44 | · | $2.01 | |
| EPS (TTM) | $1.74 | $1.88 | · | $2.32 | $6.95 | $7.00 | · | $6.93 | $2.43 | $2.32 | · | $2.34 | $2.26 | $2.41 | · | $2.31 |
バリュエーション（TTM）
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $6.51B | $6.30B | · | $5.88B | $5.69B | $5.52B | · | $5.07B | $4.95B | $4.86B | · | $4.17B | $4.25B | $4.34B | · | $5.36B | |
| Net Income TTM | $1.00B | $1.10B | · | $1.37B | $4.15B | $4.18B | · | $4.16B | $1.47B | $1.41B | · | $1.43B | $1.39B | $1.49B | · | · | |
| Market Cap | $52.16B | $46.21B | · | $45.16B | $45.98B | $42.49B | · | $38.92B | $55.63B | $57.57B | · | $42.02B | $57.34B | $50.13B | · | $51.18B | |
| Enterprise Value | $48.51B | $43.13B | · | $41.92B | $42.52B | $39.19B | · | $35.07B | $54.24B | $56.46B | · | $40.75B | $56.43B | $49.48B | · | $50.04B | |
| P/E | 52.0 | 42.6 | · | 33.5 | 11.3 | 10.4 | · | 9.5 | 38.0 | 41.2 | · | 29.6 | 41.7 | 34.3 | · | 35.8 | |
| P/S | 8.0 | 7.3 | · | 7.7 | 8.1 | 7.7 | · | 7.7 | 11.2 | 11.8 | · | 10.1 | 13.5 | 11.5 | · | 9.5 | |
| P/B | 4.9 | 4.5 | · | 4.4 | 4.4 | 4.2 | · | 4.1 | 7.5 | 8.1 | · | 6.3 | 9.0 | 8.4 | · | 8.2 | |
| P / Tangible Book | 7.2 | 6.3 | · | 6.2 | 6.1 | 5.9 | · | 5.6 | 9.5 | 10.6 | · | 8.5 | 12.3 | 11.9 | · | 10.7 | |
| P / Cash Flow | · | 1054.9 | · | · | · | 151.5 | · | · | · | -1076.0 | · | · | · | 159.6 | · | · | |
| EV / Revenue | 7.4 | 6.8 | · | 7.1 | 7.5 | 7.1 | · | 6.9 | 10.9 | 11.6 | · | 9.8 | 13.3 | 11.4 | · | 9.3 | |
| Earnings Yield | 1.9% | 2.4% | · | 3.0% | 8.9% | 9.7% | · | 10.5% | 2.6% | 2.4% | · | 3.4% | 2.4% | 2.9% | · | 2.8% |
最新期間は左側 · null値は・として表示
財務諸表 損益計算書、貸借対照表、キャッシュフロー — 年次、過去5年間
| 指標 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 収益 | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B |
| 粗利益率 % | 78.0% | 79.5% | 77.0% | 79.9% | 76.1% |
| 営業利益率 % | 20.8% | 25.4% | 25.6% | 32.5% | 32.3% |
| 純利益 | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B |
| 希薄化後EPS | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 |
| 指標 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 負債資本倍率 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| 流動比率 | 3.7 | 4.2 | 3.4 | 3.0 | 3.1 |
| クイックレシオ | 2.7 | 3.0 | 2.0 | 1.8 | 2.0 |
| 指標 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| フリーキャッシュフロー | $1.33B | $290M | $643M | $974M | $1.41B |
機関投資家（13F） 1,432 提出者 · $52.4B合計 · 時点 2026年9月30日
四半期SECフォーム13Fでこの株式の保有を報告している機関。ロングポジションのみ。単一の提出者は、別々のオプションレッグで2回表示される場合があります。 大きな反対売買のプット/コール・レッグは、通常、マーケットメイクまたはヘッジされた在庫を反映しており、方向性への確信を示すものではありません。
保有者
1,432
保有価値
$52.4B
新規ポジション
155
解消済みポジション
97
機関投資家の動向 — Q2 2026 対 前四半期
| 新規ポジション | 解消済みポジション | 増加 | 減少 | 純株式数増減 |
|---|---|---|---|---|
| 155 (+6 前期比) | 97 (-12 前期比) | 471 (+23 前期比) | 469 (+12 前期比) | +13.8M |
Q1 2026と比較しました。 SECフォーム13Fの提出期限は四半期末から45日後ですが、遅延提出者向けの短いバッファーが含まれます。この期間内の四半期は、直近で完全に報告されたペアを優先するためスキップされます。
| 機関投資家 | 評価額 | 株式数 | % 追跡された13Fのうち | タイプ |
|---|---|---|---|---|
| VANGUARD GROUP INC | $5,974,271,834 | 70,079,435 | 11.40% | 株式数 |
| BlackRock, Inc. | $5,318,092,039 | 58,789,433 | 10.15% | 株式数 |
| VANGUARD CAPITAL MANAGEMENT LLC | $3,402,739,018 | 37,615,952 | 6.50% | 株式数 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2,389,175,425 | 26,411,402 | 4.56% | 株式数 |
| STATE STREET CORP | $2,381,082,692 | 26,321,940 | 4.55% | 株式数 |
| JPMORGAN CHASE & CO | $2,077,369,996 | 22,783,175 | 3.97% | 株式数 |
| WELLINGTON MANAGEMENT GROUP LLP | $1,522,257,896 | 16,827,967 | 2.91% | 株式数 |
| GEODE CAPITAL MANAGEMENT, LLC | $1,390,906,696 | 15,437,251 | 2.66% | 株式数 |
| Bank of New York Mellon Corp | $1,274,082,304 | 14,084,483 | 2.43% | 株式数 |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | $1,176,248,067 | 13,002,965 | 2.25% | 株式数 |
| Ninety One UK Ltd | $1,116,050,276 | 12,337,502 | 2.13% | 株式数 |
| Aristotle Capital Management, LLC | $783,906,442 | 8,665,712 | 1.50% | 株式数 |
| FMR LLC | $763,115,873 | 8,435,949 | 1.46% | 株式数 |
| NORGES BANK | $757,492,410 | 8,373,783 | 1.45% | 株式数 |
| ALLIANCEBERNSTEIN L.P. | $693,526,113 | 8,660,416 | 1.32% | 株式数 |
| BROWN ADVISORY INC | $666,327,162 | 7,365,987 | 1.27% | 株式数 |
| BANK OF AMERICA CORP /DE/ | $605,396,715 | 6,692,424 | 1.16% | 株式数 |
| Artisan Partners Limited Partnership | $599,361,052 | 6,625,703 | 1.14% | 株式数 |
| MORGAN STANLEY | $573,459,576 | 6,339,368 | 1.09% | 株式数 |
| DEUTSCHE BANK AG\ | $516,552,291 | 5,710,284 | 0.99% | 株式数 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $513,572,538 | 5,677,344 | 0.98% | 株式数 |
| NORTHERN TRUST CORP | $513,019,376 | 5,671,229 | 0.98% | 株式数 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $437,088,491 | 5,458,148 | 0.83% | 株式数 |
| WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST | $434,208,000 | 4,800,000 | 0.83% | 株式数 |
| GOLDMAN SACHS GROUP INC | $411,512,754 | 4,549,113 | 0.79% | 株式数 |
| Legal & General Group Plc | $389,088,546 | 4,301,222 | 0.74% | 株式数 |
| CITADEL ADVISORS LLC | $361,652,295 | 3,997,925 | 0.69% | 株式数 |
| Invesco Ltd. | $359,806,234 | 3,977,518 | 0.69% | 株式数 |
| DIMENSIONAL FUND ADVISORS LP | $334,928,288 | 3,702,299 | 0.64% | 株式数 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $334,071,856 | 3,693,034 | 0.64% | 株式数 |
| MILLENNIUM MANAGEMENT LLC | $324,280,556 | 3,584,795 | 0.62% | 株式数 |
| ROYAL BANK OF CANADA | $316,740,000 | 3,501,447 | 0.60% | 株式数 |
| PRIMECAP MANAGEMENT CO/CA/ | $308,314,004 | 3,408,291 | 0.59% | 株式数 |
| VANGUARD FIDUCIARY TRUST CO | $292,399,738 | 3,232,365 | 0.56% | 株式数 |
| Holocene Advisors, LP | $283,979,721 | 3,139,285 | 0.54% | 株式数 |
| Nuveen, LLC | $267,803,860 | 2,960,468 | 0.51% | 株式数 |
| NEUBERGER BERMAN GROUP LLC | $261,237,879 | 2,886,953 | 0.50% | 株式数 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $250,776,107 | 2,772,232 | 0.48% | 株式数 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $238,277,000 | 2,634,054 | 0.45% | 株式数 |
| Amundi | $233,363,816 | 2,579,748 | 0.45% | 株式数 |
| Mirova US LLC | $229,802,865 | 2,540,381 | 0.44% | 株式数 |
| Allspring Global Investments Holdings, LLC | $228,999,539 | 2,489,396 | 0.44% | 株式数 |
| RAYMOND JAMES FINANCIAL INC | $219,553,940 | 2,427,083 | 0.42% | 株式数 |
| UBS Group AG | $212,640,342 | 2,350,656 | 0.41% | 株式数 |
| Russell Investments Group, Ltd. | $207,120,205 | 2,288,745 | 0.40% | 株式数 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $175,696,355 | 1,942,132 | 0.34% | 株式数 |
| SEI INVESTMENTS CO | $171,883,685 | 1,900,137 | 0.33% | 株式数 |
| Assenagon Asset Management S.A. | $163,997,286 | 1,812,926 | 0.31% | 株式数 |
| Point72 Asset Management, L.P. | $160,486,895 | 1,774,120 | 0.31% | 株式数 |
| NORDEA INVESTMENT MANAGEMENT AB | $147,126,018 | 1,629,844 | 0.28% | 株式数 |
アクティビストおよび5%超のオーナー 1保有
SECスケジュール13Dを提出した投資家 — 発行体の影響を与える意図（アクティビストの保有、取締役会キャンペーン、M&A）を持つ5%超の受益権所有。各行は、その提出者のポジションの最新の既知の状態を示します。
| 提出者 | 提出済み | 保有 | ステータス | 目的 | 提出書類 |
|---|---|---|---|---|---|
| 未開示の報告者 | 2001年4月5日 | · | 初回提出 | 取締役会キャンペーン | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
企業インサイダー 48 人のインサイダー · 20人の役員 · 8人の取締役
| インサイダー | 役職 | 最終アクティビティ | 保有株式数 | 12ヶ月購入 | 12ヶ月売却 | 12ヶ月純額 |
|---|---|---|---|---|---|---|
| Bernard J Zovighian | CEO | 2026年7月27日 S | 8,916 | 0 | 8 | $-6,996,971 |
| Theodora Mistras | CVP, Chief Financial Officer | 2026年7月9日 A | 99,920 | 0 | 0 | $0 |
| Thomas M Abate | CVP, CFO | 2013年5月14日 A | 43,047 | 0 | 0 | $0 |
| Wayne Markowitz | CVP, JAPAC | 2026年9月14日 F | 19,371 | 0 | 5 | $-1,042,352 |
| Andrew M. Dahl | SVP, Corporate Controller | 2026年9月13日 F | 14,615 | 0 | 2 | $-98,430 |
| Daniel J. Lippis | CVP, TAVR | 2026年9月11日 M | 40,034 | 0 | 13 | $-871,621 |
| Daveen Chopra | CVP, TMTT, Surgical & IHFM | 2026年9月11日 F | 43,926 | 0 | 4 | $-3,190,031 |
| Annette Bruls | CVP, EMEACLA | 2026年8月28日 S | 17,984 | 0 | 1 | $-237,907 |
| Carlyn D Solomon | CVP, Critical Care & Vascular | 2014年10月28日 M | 31,154 | 0 | 0 | $0 |
| Christine Z Mccauley | CVP, Human Resources | 2013年5月13日 F | 4,035 | 0 | 0 | $0 |
| Paul C Redmond | CVP, Global Operations | 2013年5月13日 S | 12,534 | 0 | 0 | $0 |
| Bruce P Garren | CVP, Public Affairs/Special Co | 2013年5月13日 F | 56,071 | 0 | 0 | $0 |
| John H Kehl JR | CVP, Strategy & Corp Dev | 2013年5月7日 F | 101,767 | 0 | 0 | $0 |
| Robert C Reindl | CVP, H.R. and Communications | 2012年7月27日 M | 1,124 | 0 | 0 | $0 |
| Aimee S Weisner | CVP, General Counsel | 2012年5月9日 A | 1,675 | 0 | 0 | $0 |
| Corinne H Nevinny | CVP & Pres., Global Ops | 2010年5月13日 A | 16,687 | 0 | 0 | $0 |
| Anita Bessler | CVP | 2007年8月31日 S | 29,410 | 0 | 0 | $0 |
| John Alexander Martin | CVP, North America | 2007年5月10日 A | 15,300 | 0 | 0 | $0 |
| Stuart L Foster | CVP, Critical Care / Vascular | 2007年5月10日 A | 24,604 | 0 | 0 | $0 |
| Randel William Woodgrift | Corp VP, Manufacturing Ops | 2005年8月4日 M | 3,349 | 0 | 0 | $0 |
| John T Cardis | 取締役 | 2016年8月10日 S | 91,458 | 0 | 0 | $0 |
| Barbara J Mcneil | 取締役 | 2016年2月4日 S | 46,454 | 0 | 0 | $0 |
| Robert Alexander Ingram | 取締役 | 2015年5月15日 A | 32,367 | 0 | 0 | $0 |
| Michael R Bowlin | 取締役 | 2014年11月14日 M | 81,751 | 0 | 0 | $0 |
| David E I Pyott | 取締役 | 2014年5月9日 A | 53,582 | 0 | 0 | $0 |
| NEAL PHILIP M | 取締役 | 2008年8月12日 M | 27,333 | 0 | 0 | $0 |
| Vernon R Loucks JR | 取締役 | 2008年5月9日 A | 24,133 | 0 | 0 | $0 |
| Donald E Bobo JR | · | 2026年5月27日 S | 98,611 | 0 | 12 | $-11,153,294 |
| Scott B. Ullem | · | 2026年5月11日 M | 46,740 | 0 | 7 | $-3,875,008 |
| Leslie C. Davis | · | 2026年5月8日 A | 9,834 | 0 | 0 | $0 |
| Ramona Sequeira | · | 2026年5月8日 A | 6,779 | 0 | 0 | $0 |
| David T Feinberg | · | 2026年5月8日 A | 9,087 | 0 | 0 | $0 |
| Kieran Gallahue | · | 2026年5月8日 A | 4,315 | 0 | 0 | $0 |
| Nicholas J Valeriani | · | 2026年5月8日 A | 84,423 | 0 | 0 | $0 |
| Heisz Leslie Stone | · | 2026年5月8日 A | 34,199 | 0 | 1 | $-218,117 |
| Steven R Loranger | · | 2026年5月8日 A | 8,997 | 0 | 0 | $0 |
| Paul A Laviolette | · | 2026年5月8日 A | 17,552 | 0 | 0 | $0 |
| Larry L Wood | · | 2025年8月18日 M | 206,900 | 0 | 0 | $0 |
| Catherine M. Szyman | · | 2024年9月3日 F | 81,287 | 0 | 0 | $0 |
| Jean-Luc M Lemercier | · | 2024年7月7日 F | 184,686 | 0 | 0 | $0 |
| Robert W.A. Sellers | · | 2024年5月11日 F | 17,081 | 0 | 0 | $0 |
| Michael A Mussallem | · | 2024年5月2日 M | 4,486 | 0 | 0 | $0 |
| Martha H. Marsh | · | 2023年5月12日 A | 31,880 | 0 | 0 | $0 |
| Huimin Wang | · | 2022年7月8日 M | 99,381 | 0 | 0 | $0 |
| William J Link PHD | · | 2020年5月8日 A | 11,349 | 0 | 0 | $0 |
| Wesley W Von Schack | · | 2019年8月1日 S | 8,000 | 0 | 0 | $0 |
| Patrick B Verguet | · | 2017年5月31日 M | 129,137 | 0 | 0 | $0 |
| Randall J Nelson | · | 2003年9月30日 A | · | 0 | 0 | $0 |
SECフォーム3/4/5提出書類からのインサイダー；純額＝公開市場のP/Sのみ
ETF保有状況 128のETFが保有
ウェイトは直接株式保有（N-PORT）のみを反映しています。レバレッジ型またはデリバティブベースのファンドは、表示されていない追加のスワップエクスポージャーを保有している可能性があります。
| ファンド | ウェイト | 単位 | 時点 | ソース |
|---|---|---|---|---|
| IHI · iShares Trust | 4.43% | 1,622,151 SH | 2026年9月11日 | 日次 |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 1.73% | 1,827 NS | 2026年7月31日 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.64% | 165,684 SH | 2026年10月1日 | 日次 |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1.55% | 12,485 NS | 2026年7月31日 | N-PORT |
| VOT · VANGUARD INDEX FUNDS | 1.14% | 4,411,246 SH | 2026年8月19日 | 日次 |
| CVAR · ETF Opportunities Trust | 0.90% | 4,502 NS | 2026年7月31日 | N-PORT |
| JOET · Virtus ETF Trust II | 0.81% | 22,947 NS | 2026年7月31日 | N-PORT |
| IYH · iShares Trust | 0.80% | 333,769 SH | 2026年9月11日 | 日次 |
| NULV · Nushares ETF Trust | 0.78% | 199,212 NS | 2026年7月31日 | N-PORT |
| SDG · iShares Trust | 0.77% | 14,866 SH | 2026年9月11日 | 日次 |
| VHT · VANGUARD WORLD FUND | 0.77% | 1,733,147 SH | 2026年8月19日 | 日次 |
| NULC · Nushares ETF Trust | 0.75% | 6,147 NS | 2026年7月31日 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.72% | 274,258 NS | 2026年7月31日 | N-PORT |
| IMCG · iShares Trust | 0.67% | 307,122 SH | 2026年9月11日 | 日次 |
| IXJ · iShares Trust | 0.63% | 303,150 SH | 2026年9月11日 | 日次 |
| JGLO · J.P. Morgan Exchange-Traded Fund Tr… | 0.58% | 451,454 NS | 2026年7月31日 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0.57% | 11,330 NS | 2026年7月31日 | N-PORT |
| HUSV · First Trust Exchange-Traded Fund III | 0.55% | 4,726 NS | 2026年7月31日 | N-PORT |
| NULG · Nushares ETF Trust | 0.52% | 160,328 NS | 2026年7月31日 | N-PORT |
| SUSA · iShares Trust | 0.50% | 233,488 SH | 2026年9月11日 | 日次 |
| VO · VANGUARD INDEX FUNDS | 0.50% | 12,477,902 SH | 2026年8月19日 | 日次 |
| IWS · iShares Trust | 0.49% | 851,606 SH | 2026年9月11日 | 日次 |
| HELO · J.P. Morgan Exchange-Traded Fund Tr… | 0.38% | 204,605 NS | 2026年7月31日 | N-PORT |
| FTC · First Trust Exchange-Traded AlphaDE… | 0.37% | 56,826 NS | 2026年7月31日 | N-PORT |
| IWR · iShares Trust | 0.36% | 2,336,086 SH | 2026年9月11日 | 日次 |
| EGUS · iShares Trust | 0.36% | 1,132 SH | 2026年9月11日 | 日次 |
| JOYT · J.P. Morgan Exchange-Traded Fund Tr… | 0.34% | 3,899 NS | 2026年7月31日 | N-PORT |
| IMCB · iShares Trust | 0.34% | 64,965 SH | 2026年9月11日 | 日次 |
| EVUS · iShares Trust | 0.30% | 13,166 SH | 2026年9月11日 | 日次 |
| FFLG · FIDELITY COVINGTON TRUST | 0.28% | 19,459 NS | 2026年7月31日 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0.28% | 154,640 SH | 2026年10月1日 | 日次 |
| XOEF · iShares Trust | 0.28% | 720 SH | 2026年9月11日 | 日次 |
| ESUM · Strategy Shares | 0.27% | 5,627 NS | 2026年7月31日 | N-PORT |
| WINN · Harbor ETF Trust | 0.24% | 31,833 NS | 2026年7月31日 | N-PORT |
| DFLV · Dimensional ETF Trust | 0.24% | 188,776 NS | 2026年7月31日 | N-PORT |
| CATH · Global X Funds | 0.24% | 35,583 NS | 2026年7月31日 | N-PORT |
| HEQQ · J.P. Morgan Exchange-Traded Fund Tr… | 0.22% | 749 NS | 2026年7月31日 | N-PORT |
| RSP · Invesco Exchange-Traded Fund Trust | 0.21% | 2,272,009 SH | 2026年10月1日 | 日次 |
| ESGU · iShares Trust | 0.20% | 421,118 SH | 2026年9月11日 | 日次 |
| USXF · iShares Trust | 0.20% | 34,234 SH | 2026年9月11日 | 日次 |
| SIZE · iShares Trust | 0.20% | 9,721 SH | 2026年9月11日 | 日次 |
| EUSA · iShares, Inc. | 0.19% | 42,285 SH | 2026年9月11日 | 日次 |
| VTV · VANGUARD INDEX FUNDS | 0.19% | 5,470,146 SH | 2026年8月19日 | 日次 |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.18% | 12,350 NS | 2026年7月31日 | N-PORT |
| DFUV · Dimensional ETF Trust | 0.18% | 327,155 NS | 2026年7月31日 | N-PORT |
| FEX · First Trust Exchange-Traded AlphaDE… | 0.17% | 31,155 NS | 2026年7月31日 | N-PORT |
| CHRI · Global X Funds | 0.15% | 140 NS | 2026年7月31日 | N-PORT |
| ILCG · iShares Trust | 0.15% | 53,996 SH | 2026年9月11日 | 日次 |
| QUAL · iShares Trust | 0.15% | 807,173 SH | 2026年9月11日 | 日次 |
| IQSU · New York Life Investments ETF Trust | 0.15% | 5,623 NS | 2026年7月31日 | N-PORT |
| SUSL · iShares Trust | 0.15% | 20,323 SH | 2026年9月11日 | 日次 |
| ESLV · Strategy Shares | 0.14% | 236 NS | 2026年7月31日 | N-PORT |
| DSI · iShares Trust | 0.14% | 87,882 SH | 2026年9月11日 | 日次 |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0.14% | 344,148 SH | 2026年8月19日 | 日次 |
| BSCS · Invesco Exchange-Traded Self-Indexe… | 0.14% | 4,863,000 | 2026年10月1日 | 日次 |
| ACWV · iShares, Inc. | 0.14% | 52,593 SH | 2026年9月11日 | 日次 |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0.14% | 172,000 | 2026年10月1日 | 日次 |
| IWD · iShares Trust | 0.13% | 1,266,618 SH | 2026年9月11日 | 日次 |
| HAPI · Harbor ETF Trust | 0.13% | 7,541 NS | 2026年7月31日 | N-PORT |
| AQLT · iShares Trust | 0.12% | 4,632 SH | 2026年9月11日 | 日次 |
| GLBL · Pacer Funds Trust | 0.12% | 15 NS | 2026年7月31日 | N-PORT |
| EGLE · Global X Funds | 0.11% | 29 NS | 2026年7月31日 | N-PORT |
| VOOV · VANGUARD ADMIRAL FUNDS | 0.10% | 71,482 SH | 2026年8月19日 | 日次 |
| QVML · Invesco Exchange-Traded Fund Trust … | 0.10% | 19,009 SH | 2026年10月1日 | 日次 |
| USCL · iShares Trust | 0.09% | 30,549 SH | 2026年9月11日 | 日次 |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0.09% | 8,617 SH | 2026年10月1日 | 日次 |
| TOPC · iShares Trust | 0.09% | 349 SH | 2026年9月11日 | 日次 |
| IVE · iShares Trust | 0.09% | 515,927 SH | 2026年9月11日 | 日次 |
| ESMV · iShares Trust | 0.09% | 81 SH | 2026年9月11日 | 日次 |
| LGDX · Tidal Trust III | 0.09% | 1,493 NS | 2026年7月31日 | N-PORT |
| ESGV · VANGUARD WORLD FUND | 0.09% | 128,864 SH | 2026年8月19日 | 日次 |
| ACVF · ETF Opportunities Trust | 0.09% | 1,589 NS | 2026年7月31日 | N-PORT |
| DFSU · Dimensional ETF Trust | 0.09% | 22,900 NS | 2026年7月31日 | N-PORT |
| XVV · iShares Trust | 0.09% | 6,682 SH | 2026年9月11日 | 日次 |
| IUSV · iShares Trust | 0.09% | 271,422 SH | 2026年9月11日 | 日次 |
| XRMI · Global X Funds | 0.08% | 475 NS | 2026年7月31日 | N-PORT |
| VOO · VANGUARD INDEX FUNDS | 0.08% | 14,955,304 SH | 2026年8月19日 | 日次 |
| VV · VANGUARD INDEX FUNDS | 0.08% | 672,462 SH | 2026年8月19日 | 日次 |
| XYLG · Global X Funds | 0.08% | 591 NS | 2026年7月31日 | N-PORT |
| XTR · Global X Funds | 0.08% | 44 NS | 2026年7月31日 | N-PORT |
| PTLC · Pacer Funds Trust | 0.08% | 29,356 NS | 2026年7月31日 | N-PORT |
| XYLD · Global X Funds | 0.08% | 28,920 NS | 2026年7月31日 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0.08% | 86,729 SH | 2026年10月1日 | 日次 |
| PBP · Invesco Exchange-Traded Fund Trust | 0.08% | 3,428 SH | 2026年10月1日 | 日次 |
| IVV · iShares Trust | 0.08% | 7,257,429 SH | 2026年9月11日 | 日次 |
| DFVX · Dimensional ETF Trust | 0.08% | 4,635 NS | 2026年7月31日 | N-PORT |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0.08% | 99,424 SH | 2026年10月1日 | 日次 |
| BKLC · BNY Mellon ETF Trust | 0.07% | 47,622 NS | 2026年7月31日 | N-PORT |
| XCLR · Global X Funds | 0.07% | 31 NS | 2026年7月31日 | N-PORT |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0.07% | 76,534 NS | 2026年7月31日 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.07% | 106,648 NS | 2026年7月31日 | N-PORT |
| VOTE · TCW ETF Trust | 0.07% | 9,386 NS | 2026年7月31日 | N-PORT |
| ILCB · iShares Trust | 0.07% | 10,752 SH | 2026年9月11日 | 日次 |
| DFUS · Dimensional ETF Trust | 0.07% | 175,602 NS | 2026年7月31日 | N-PORT |
| IYY · iShares Trust | 0.07% | 24,812 SH | 2026年9月11日 | 日次 |
| VOXP · Advisors Series Trust | 0.07% | 48 NS | 2026年7月31日 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0.07% | 2,173 NS | 2026年7月31日 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.07% | 27,431 NS | 2026年7月31日 | N-PORT |
| IWB · iShares Trust | 0.07% | 393,450 SH | 2026年9月11日 | 日次 |
| VTI · VANGUARD INDEX FUNDS | 0.07% | 18,282,795 SH | 2026年8月19日 | 日次 |
| VOOG · VANGUARD ADMIRAL FUNDS | 0.07% | 197,076 SH | 2026年8月19日 | 日次 |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0.07% | 94,564 SH | 2026年8月19日 | 日次 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.07% | 48,000 SH | 2026年8月19日 | 日次 |
| QDPL · Pacer Funds Trust | 0.07% | 13,875 NS | 2026年7月31日 | N-PORT |
| TOV · EA Series Trust | 0.07% | 2,241 NS | 2026年7月31日 | N-PORT |
| ITOT · iShares Trust | 0.07% | 752,546 SH | 2026年9月11日 | 日次 |
| IWV · iShares Trust | 0.07% | 156,590 SH | 2026年9月11日 | 日次 |
| DFAC · Dimensional ETF Trust | 0.07% | 365,592 NS | 2026年7月31日 | N-PORT |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0.07% | 7,283 SH | 2026年10月1日 | 日次 |
| IVW · iShares Trust | 0.06% | 564,876 SH | 2026年9月11日 | 日次 |
| PHDG · Invesco Actively Managed Exchange-T… | 0.06% | 446 SH | 2026年10月1日 | 日次 |
| IUSG · iShares Trust | 0.06% | 232,595 SH | 2026年9月11日 | 日次 |
| HCMT · Direxion Shares ETF Trust | 0.06% | 4,008 NS | 2026年7月31日 | N-PORT |
| TOK · iShares Trust | 0.06% | 1,613 SH | 2026年9月11日 | 日次 |
| SPXL · Direxion Shares ETF Trust | 0.06% | 45,012 NS | 2026年7月31日 | N-PORT |
| URTH · iShares, Inc. | 0.06% | 52,555 SH | 2026年9月11日 | 日次 |
| TILT · FlexShares Trust | 0.05% | 13,604 NS | 2026年7月31日 | N-PORT |
| ACWI · iShares Trust | 0.05% | 184,834 SH | 2026年9月11日 | 日次 |
| ROUS · Lattice Strategies Trust | 0.04% | 3,407 NS | 2026年7月31日 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.04% | 480,405 SH | 2026年8月19日 | 日次 |
| CRBN · iShares Trust | 0.04% | 4,703 SH | 2026年9月11日 | 日次 |
| RWL · Invesco Exchange-Traded Fund Trust … | 0.03% | 37,758 SH | 2026年10月1日 | 日次 |
| DXUV · Dimensional ETF Trust | 0.03% | 1,805 NS | 2026年7月31日 | N-PORT |
| PEVC · Pacer Funds Trust | 0.01% | 2 NS | 2026年7月31日 | N-PORT |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | 2026年7月15日 | 日次 |
| BND · VANGUARD BOND INDEX FUNDS | · | · | 2026年7月15日 | 日次 |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | 2026年7月15日 | 日次 |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | 2026年7月14日 | 日次 |
EW アナリストコンセンサス 強気・弱気のアナリストの見解、12ヶ月の目標株価、アップサイド
レーティング · 40 アナリスト
買い
中央値ターゲット
$101.50
+19.2%
13 32.5%
強い買い
18 45.0%
買い
9 22.5%
保有
0 0.0%
売り
0 0.0%
強い売り
12ヶ月目標株価
26 アナリスト · 2026-09-30平均値ターゲット $100.96 +18.6%
現在
現在価格 $85.15
安値$84.00
平均値$100.96
高値$110.00
同業他社比較（GICSサブインダストリー） 主要メトリクスとセクターピアの比較
FY基準、価格は各社の直近年度末終値。
| ティッカー | 時価総額 | P/E | 売上高 YoY | 純利益率 | ROE | 粗利益率 |
|---|---|---|---|---|---|---|
| EW | $49.50B | 46.6 | 11.6% | 17.7% | 10.6% | 78.0% |
| ABT | $250.18B | 33.7 | 5.7% | 14.7% | 13.1% | · |
| ISRG | $201.11B | 72.0 | 20.5% | 28.4% | 16.7% | 66.0% |
| SYK | $134.44B | 41.8 | 11.2% | 12.9% | 15.1% | 64.0% |
| BSX | · | 49.1 | 19.9% | 14.4% | 12.6% | 69.0% |
| BDX | · | 25.3 | 8.2% | 7.7% | 6.5% | · |
| IDXX | $53.93B | 51.7 | 10.4% | 24.6% | 69.2% | 61.8% |
| DXCM | $25.54B | 31.8 | 15.6% | 17.9% | 31.4% | 60.1% |
| RMD | $28.11B | 18.7 | 9.8% | 26.9% | 23.6% | 61.1% |
| GEHC | · | 18.0 | 4.8% | 10.1% | 22.1% | 40.0% |
| ZBH | $28.66B | 25.3 | 7.2% | 8.6% | 5.6% | · |
トレードシグナル エントリー価格とリスク/リワード比率を伴う最近の売買シグナル
現在オープンシグナルはありません — カードは塗りつぶされておらず、それが正直なところです。
マイ指標 あなた専用のウォッチリスト — 決算詳細から選択した行
重視する指標を選択してください — 上記の「財務諸表」の任意の行の横にある「+」をクリックしてください。
選択内容は保存され、すべてのティッカーで引き継がれます。
出典：SEC 10-Q 提出日 8月 4, 2026